Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia

Ronald S. Go, Ayalew Tefferi, Chin Yang Li, John A. Lust, Robert L. Phyliky

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Lymphoproliferative disease of granular T lymphocyte (T-LDGL), also known as T-cell large granular lymphocyte leukemia, is a clonal disorder of cytotoxic T lymphocytes that is clinically manifested as chronic neutropenia and anemia. Association with autoimmune disorders is common. In 9 patients, T-LDGL is reported as presenting as aplasfic anemia. The clinical characteristics were similar to acquired aplastic anemia. Morphologic evidence of increased granular lymphocytes in the peripheral blood and an excess of CD3+/CD8+/CD57+ cells in the bone marrow were found in most cases. Cyclophosphamide was ineffective, but noncytotoxic immunosuppressive agents generally produced a good response. After a median follow-up of 49 months, 5 patients had died from the disease or related complications. Median survival was 40 months. Aplastic anemia can be a presenting manifestation of T-LDGL, and T-LDGL should be considered in the differential diagnosis of acquired aplastic anemia. (C) 2000 by The American Society of Hematology.

Original languageEnglish (US)
Pages (from-to)3644-3646
Number of pages3
JournalBlood
Volume96
Issue number10
StatePublished - Nov 15 2000

Fingerprint

Large Granular Lymphocytic Leukemia
T-cells
Aplastic Anemia
Lymphocytes
T-Lymphocytes
Anemia
Cytotoxic T-Lymphocytes
Immunosuppressive Agents
Neutropenia
Bone Marrow Cells
Cyclophosphamide
Bone
Differential Diagnosis
Blood
Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Go, R. S., Tefferi, A., Li, C. Y., Lust, J. A., & Phyliky, R. L. (2000). Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia. Blood, 96(10), 3644-3646.

Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia. / Go, Ronald S.; Tefferi, Ayalew; Li, Chin Yang; Lust, John A.; Phyliky, Robert L.

In: Blood, Vol. 96, No. 10, 15.11.2000, p. 3644-3646.

Research output: Contribution to journalArticle

Go, RS, Tefferi, A, Li, CY, Lust, JA & Phyliky, RL 2000, 'Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia', Blood, vol. 96, no. 10, pp. 3644-3646.
Go RS, Tefferi A, Li CY, Lust JA, Phyliky RL. Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia. Blood. 2000 Nov 15;96(10):3644-3646.
Go, Ronald S. ; Tefferi, Ayalew ; Li, Chin Yang ; Lust, John A. ; Phyliky, Robert L. / Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia. In: Blood. 2000 ; Vol. 96, No. 10. pp. 3644-3646.
@article{67323b1592504d6881e9c29d0385593b,
title = "Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia",
abstract = "Lymphoproliferative disease of granular T lymphocyte (T-LDGL), also known as T-cell large granular lymphocyte leukemia, is a clonal disorder of cytotoxic T lymphocytes that is clinically manifested as chronic neutropenia and anemia. Association with autoimmune disorders is common. In 9 patients, T-LDGL is reported as presenting as aplasfic anemia. The clinical characteristics were similar to acquired aplastic anemia. Morphologic evidence of increased granular lymphocytes in the peripheral blood and an excess of CD3+/CD8+/CD57+ cells in the bone marrow were found in most cases. Cyclophosphamide was ineffective, but noncytotoxic immunosuppressive agents generally produced a good response. After a median follow-up of 49 months, 5 patients had died from the disease or related complications. Median survival was 40 months. Aplastic anemia can be a presenting manifestation of T-LDGL, and T-LDGL should be considered in the differential diagnosis of acquired aplastic anemia. (C) 2000 by The American Society of Hematology.",
author = "Go, {Ronald S.} and Ayalew Tefferi and Li, {Chin Yang} and Lust, {John A.} and Phyliky, {Robert L.}",
year = "2000",
month = "11",
day = "15",
language = "English (US)",
volume = "96",
pages = "3644--3646",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia

AU - Go, Ronald S.

AU - Tefferi, Ayalew

AU - Li, Chin Yang

AU - Lust, John A.

AU - Phyliky, Robert L.

PY - 2000/11/15

Y1 - 2000/11/15

N2 - Lymphoproliferative disease of granular T lymphocyte (T-LDGL), also known as T-cell large granular lymphocyte leukemia, is a clonal disorder of cytotoxic T lymphocytes that is clinically manifested as chronic neutropenia and anemia. Association with autoimmune disorders is common. In 9 patients, T-LDGL is reported as presenting as aplasfic anemia. The clinical characteristics were similar to acquired aplastic anemia. Morphologic evidence of increased granular lymphocytes in the peripheral blood and an excess of CD3+/CD8+/CD57+ cells in the bone marrow were found in most cases. Cyclophosphamide was ineffective, but noncytotoxic immunosuppressive agents generally produced a good response. After a median follow-up of 49 months, 5 patients had died from the disease or related complications. Median survival was 40 months. Aplastic anemia can be a presenting manifestation of T-LDGL, and T-LDGL should be considered in the differential diagnosis of acquired aplastic anemia. (C) 2000 by The American Society of Hematology.

AB - Lymphoproliferative disease of granular T lymphocyte (T-LDGL), also known as T-cell large granular lymphocyte leukemia, is a clonal disorder of cytotoxic T lymphocytes that is clinically manifested as chronic neutropenia and anemia. Association with autoimmune disorders is common. In 9 patients, T-LDGL is reported as presenting as aplasfic anemia. The clinical characteristics were similar to acquired aplastic anemia. Morphologic evidence of increased granular lymphocytes in the peripheral blood and an excess of CD3+/CD8+/CD57+ cells in the bone marrow were found in most cases. Cyclophosphamide was ineffective, but noncytotoxic immunosuppressive agents generally produced a good response. After a median follow-up of 49 months, 5 patients had died from the disease or related complications. Median survival was 40 months. Aplastic anemia can be a presenting manifestation of T-LDGL, and T-LDGL should be considered in the differential diagnosis of acquired aplastic anemia. (C) 2000 by The American Society of Hematology.

UR - http://www.scopus.com/inward/record.url?scp=0034669942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034669942&partnerID=8YFLogxK

M3 - Article

C2 - 11071666

AN - SCOPUS:0034669942

VL - 96

SP - 3644

EP - 3646

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -